Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20269 Citations
Atosiban (Tractocile)9 residues (approx.)CYITNCPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Atosiban (Tractocile) is a hospital-only IV tocolytic that blocks oxytocin receptors to delay preterm delivery by 48+ hours. EMA-approved since 2000 but rejected by the FDA. APOSTEL 8 (2025, n=752) challenged its neonatal benefit at later gestational ages, finding no improvement in composite outcomes versus placebo.
6.75mcg · Single dose
Summary: Add 0mL BAC water to your 0.9mg vial. Draw to < 0.1 units on a U-100 syringe for a 6.75mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 6.75mg | Single dose |
| Moderate | 6.75mg | Single dose |
| Aggressive | 6.75mg | Single dose |
Atosiban is a hospital-only IV drug. There is no subcutaneous version, no self-injection protocol, no home use. Your obstetric team manages everything. The three-phase protocol is fixed: 6.75 mg bolus over 1 minute, then 300 mcg/min infusion for 3 hours, then 100 mcg/min for up to 45 hours. Maximum total dose per course is 330.75 mg. Treatment cannot exceed 48 hours. Two separate vial types exist and they are not interchangeable. The bolus vial is 0.9 mL containing 6.75 mg (7.5 mg/mL concentration). The infusion concentrate vial is 5 mL containing 37.5 mg (7.5 mg/mL). For Phase 2 and 3, dilute each 5 mL concentrate vial into 45 mL of 0.9% sodium chloride, Ringer's lactate, or 5% dextrose. Final concentration: 0.75 mg/mL. Loading rate: 24 mL/hour. Maintenance rate: 8 mL/hour. If contractions return after stopping, retreatment with the identical protocol is permitted. Up to 3 courses are documented clinically. One thing most non-specialists miss: after the infusion ends, residual OTR blockade can reduce uterine tone at delivery. Make sure delivery notes flag prior atosiban use so uterotonic agents are standing by.
Dosing based on EMA-approved Tractocile dosing; not FDA-approved: dose from EU label — 13 published references.View all sources →
Cross-check your Atosiban (Tractocile) reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Atosiban (Tractocile) is a hospital-only IV tocolytic that blocks oxytocin receptors to delay preterm delivery by 48+ hours. EMA-approved since 2000 but rejected by the FDA. APOSTEL 8 (2025, n=752) challenged its neonatal benefit at later gestational ages, finding no improvement in composite outcomes versus placebo.
